辉瑞赢下Paxlovid专利侵权案，Enanta拟提起上诉_老虎社区_美港股上老虎

辉瑞赢下Paxlovid专利侵权案，Enanta拟提起上诉

智通财经2024-12-24

12月24日，Enanta Pharmaceuticals周二表示，将对美国联邦法院支持辉瑞)在与新冠抗病毒药物Paxlovid相关的专利侵权案中的裁决提出上诉。据了解，两者的专利之争始于2022年，当时Enanta在马萨诸塞州地方法院起诉辉瑞，要求赔偿其在制造、使用和销售Paxlovid过程中涉嫌侵犯其美国专利号11358953的损失。该公司表示，在对辉瑞提出的即决判决动议的裁决中，法院裁定其...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

lairdnote
·2024-12-25
疫苗跑不掉
回复
1
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2493086652?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2024-12-24 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493086652","market":"us","top_or_hot":-1,"title":"辉瑞赢下Paxlovid专利侵权案，Enanta拟提起上诉","media":"智通财经","content":"<div>\n<p>12月24日，Enanta Pharmaceuticals周二表示，将对美国联邦法院支持辉瑞)在与新冠抗病毒药物Paxlovid相关的专利侵权案中的裁决提出上诉。据了解，两者的专利之争始于2022年，当时Enanta在马萨诸塞州地方法院起诉辉瑞，要求赔偿其在制造、使用和销售Paxlovid过程中涉嫌侵犯其美国专利号11358953的损失。该公司表示，在对辉瑞提出的即决判决动议的裁决中，法院裁定其...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1229188.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞赢下Paxlovid专利侵权案，Enanta拟提起上诉</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞赢下Paxlovid专利侵权案，Enanta拟提起上诉\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-24 21:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1229188.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月24日，Enanta Pharmaceuticals周二表示，将对美国联邦法院支持辉瑞)在与新冠抗病毒药物Paxlovid相关的专利侵权案中的裁决提出上诉。据了解，两者的专利之争始于2022年，当时Enanta在马萨诸塞州地方法院起诉辉瑞，要求赔偿其在制造、使用和销售Paxlovid过程中涉嫌侵犯其美国专利号11358953的损失。该公司表示，在对辉瑞提出的即决判决动议的裁决中，法院裁定其...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1229188.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE000M9KFDE8.USD","symbol_name":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1229188.html","article_id":"2493086652","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493086652","pubTimestamp":1735046121,"columns":[{"name":"政策监管","id":32,"label_key":"policyRegulatory"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，Enanta Pharmaceuticals周二表示，将对美国联邦法院支持辉瑞在与新冠抗病毒药物Paxlovid相关的专利侵权案中的裁决提出上诉。据了解，两者的专利之争始于2022年，当时Enanta在马萨诸塞州地方法院起诉辉瑞，要求赔偿其在制造、使用和销售Paxlovid过程中涉嫌侵犯其美国专利号11358953的损失。该公司表示，在对辉瑞提出的即决判决动议的裁决中，法院裁定其11358953专利无效。Enanta补充道，它将向美国上诉法院提起上诉。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4592":"伊斯兰概念","BK4599":"减肥药","BK4585":"ETF&股票定投概念","PFE":"辉瑞","BK4534":"瑞士信贷持仓","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4139":"生物科技","BK4007":"制药","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4533":"AQR资本管理(全球第二大对冲基金)","ENTA":"Enanta Pharmaceuticals Inc.","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4581":"高盛持仓","LU0058720904.USD":"联博国际健康护理基金A","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC"},"translate_title":"Pfizer wins Paxlovid patent infringement case, Enanta plans to appeal","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/00ced0c27e39c6f0d2cd4ab44918c167","symbols_score_info":{"PFE":1,"ENTA":1},"content_text":"12月24日，Enanta Pharmaceuticals周二表示，将对美国联邦法院支持辉瑞)在与新冠抗病毒药物Paxlovid相关的专利侵权案中的裁决提出上诉。据了解，两者的专利之争始于2022年，当时Enanta在马萨诸塞州地方法院起诉辉瑞，要求赔偿其在制造、使用和销售Paxlovid过程中涉嫌侵犯其美国专利号11358953的损失。该公司表示，在对辉瑞提出的即决判决动议的裁决中，法院裁定其11358953专利无效。Enanta补充道，它将向美国上诉法院提起上诉。首席执行官Jay Luly表示：“我们对法院的裁决感到失望。我们坚信我们案件的是非曲直，通过上诉程序，我们将继续为我们的发明辩护，防止非法侵权。”","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":385171393098136,"gmtCreate":1735056144827,"gmtModify":1735056146696,"author":{"id":"3476160660269994","authorId":"3476160660269994","name":"lairdnote","avatar":"https://static.tigerbbs.com/7df32f4ad730b6386b7700f9da22bd6f","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":7,"crmLevelSwitch":1,"authorIdStr":"3476160660269994","idStr":"3476160660269994"},"htmlText":"疫苗跑不掉","listText":"疫苗跑不掉","text":"疫苗跑不掉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/385171393098136","repostId":2493086652,"repostType":2,"repost":{"id":"2493086652","kind":"news","pubTimestamp":1735046121,"share":"https://www.laohu8.com/m/news/2493086652?lang=&edition=full","pubTime":"2024-12-24 21:15","market":"us","language":"zh","title":"辉瑞赢下Paxlovid专利侵权案，Enanta拟提起上诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2493086652","media":"智通财经","summary":"智通财经APP获悉，Enanta Pharmaceuticals周二表示，将对美国联邦法院支持辉瑞在与新冠抗病毒药物Paxlovid相关的专利侵权案中的裁决提出上诉。据了解，两者的专利之争始于2022年，当时Enanta在马萨诸塞州地方法院起诉辉瑞，要求赔偿其在制造、使用和销售Paxlovid过程中涉嫌侵犯其美国专利号11358953的损失。该公司表示，在对辉瑞提出的即决判决动议的裁决中，法院裁定其11358953专利无效。Enanta补充道，它将向美国上诉法院提起上诉。","content":"<html><head></head><body><p>12月24日，<a href=\"https://laohu8.com/S/ENTA\">Enanta Pharmaceuticals</a>周二表示，将对美国联邦法院支持<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>)在与新冠抗病毒药物Paxlovid相关的专利侵权案中的裁决提出上诉。</p><p>据了解，两者的专利之争始于2022年，当时Enanta在马萨诸塞州地方法院起诉辉瑞，要求赔偿其在制造、使用和销售Paxlovid过程中涉嫌侵犯其美国专利号11358953的损失。</p><p>该公司表示，在对辉瑞提出的即决判决动议的裁决中，法院裁定其11358953专利无效。Enanta补充道，它将向美国上诉法院提起上诉。</p><p>首席执行官Jay Luly表示：“我们对法院的裁决感到失望。我们坚信我们案件的是非曲直，通过上诉程序，我们将继续为我们的发明辩护，防止非法侵权。”</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞赢下Paxlovid专利侵权案，Enanta拟提起上诉</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞赢下Paxlovid专利侵权案，Enanta拟提起上诉\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-24 21:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1229188.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月24日，Enanta Pharmaceuticals周二表示，将对美国联邦法院支持辉瑞)在与新冠抗病毒药物Paxlovid相关的专利侵权案中的裁决提出上诉。据了解，两者的专利之争始于2022年，当时Enanta在马萨诸塞州地方法院起诉辉瑞，要求赔偿其在制造、使用和销售Paxlovid过程中涉嫌侵犯其美国专利号11358953的损失。该公司表示，在对辉瑞提出的即决判决动议的裁决中，法院裁定其...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1229188.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4592":"伊斯兰概念","BK4599":"减肥药","BK4585":"ETF&股票定投概念","PFE":"辉瑞","BK4534":"瑞士信贷持仓","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4139":"生物科技","BK4007":"制药","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4533":"AQR资本管理(全球第二大对冲基金)","ENTA":"Enanta Pharmaceuticals Inc.","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4581":"高盛持仓","LU0058720904.USD":"联博国际健康护理基金A","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC"},"source_url":"http://www.zhitongcaijing.com/content/detail/1229188.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2493086652","content_text":"12月24日，Enanta Pharmaceuticals周二表示，将对美国联邦法院支持辉瑞)在与新冠抗病毒药物Paxlovid相关的专利侵权案中的裁决提出上诉。据了解，两者的专利之争始于2022年，当时Enanta在马萨诸塞州地方法院起诉辉瑞，要求赔偿其在制造、使用和销售Paxlovid过程中涉嫌侵犯其美国专利号11358953的损失。该公司表示，在对辉瑞提出的即决判决动议的裁决中，法院裁定其11358953专利无效。Enanta补充道，它将向美国上诉法院提起上诉。首席执行官Jay Luly表示：“我们对法院的裁决感到失望。我们坚信我们案件的是非曲直，通过上诉程序，我们将继续为我们的发明辩护，防止非法侵权。”","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}